Visual prosthesis

Pixium Vision and partners publish paper on photovoltaic subretinal prosthesis PRIMA in Nature Biomedical Engineering

Retrieved on: 
Monday, December 2, 2019
Electromagnetic radiation, Emerging technologies, Prosthetics, Electrodynamics, Articles, Eye, Visual prosthesis, Infrared, Biomedical engineering, Retina

The paper, available here , reports on the evaluation, in three awake non-human primates, of PRIMA, a previously reported near-infrared-light-sensitive photovoltaic subretinal prosthesis.

Key Points: 
  • The paper, available here , reports on the evaluation, in three awake non-human primates, of PRIMA, a previously reported near-infrared-light-sensitive photovoltaic subretinal prosthesis.
  • It shows that single pixel stimulation of the prosthesis within radiation safety limits enabled eye tracking in behaving animals.
  • says Serge Picaud, INSERM Research Director at the Paris Vision Institute and the corresponding author of the paper.
  • Nature Biomedical Engineeringis an online-only monthly journal publishing original research, reviews and commentary of high significance to the biomedical engineering community.

Second Sight Reports Third Quarter 2019 Financial Results

Retrieved on: 
Thursday, November 14, 2019
Optical, Health, Medical devices, Emerging technologies, Eye, Prosthetics, Visual prosthesis, Technology, Biotechnology, Articles, Second Sight, the Orion Visual Cortical Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three and nine months ended September 30, 2019.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three and nine months ended September 30, 2019.
  • Net sales on a GAAP basis were $0.5 million for the third quarter of 2019 compared to $2.2 million in the third quarter of 2018.
  • Selling and marketing expense was $1.3 million during the third quarter of 2019 compared to $3.0 million in the third quarter of 2018.
  • As previously announced, Second Sight management will host its third quarter 2019 conference call as follows:

Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call

Retrieved on: 
Tuesday, November 5, 2019
Optical, Health, Medical devices, Medical technology, Prosthetics, Biotechnology, Biological engineering, Emerging technologies, Medical devices, Biomedical engineering, Visual prosthesis, Implant

A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International).

Key Points: 
  • A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International).
  • The archived webcast will be available for 30 days via the aforementioned URL.
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Second Sight to Present at September Investor Conferences

Retrieved on: 
Wednesday, August 28, 2019
Health, Optical, Branches of biology, Medicine, Medical technology, Prosthetics, Emerging technologies, Neurotechnology, Medical devices, Neuroprosthetics, Visual prosthesis, Visual impairment, Neuromodulation, Implant, Second Sight, the Orion Visual Cortical Prosthesis System

Second Sight Medical Products, Inc. (NASDAQ:EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ:EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals.
  • The Companys U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland.
  • Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses.

Second Sight to Discuss Second Quarter 2019 Financial Results on August 6, 2019 Conference Call

Retrieved on: 
Tuesday, July 30, 2019
Optical, Health, Medical devices, Medical technology, Prosthetics, Biotechnology, Biological engineering, Emerging technologies, Medical devices, Biomedical engineering, Visual prosthesis, Implant

A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International).

Key Points: 
  • A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International).
  • The archived webcast will be available for 30 days via the aforementioned URL.
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Second Sight to Present at 20th Annual B. Riley FBR Investor Conference

Retrieved on: 
Thursday, May 16, 2019
Health, Biotechnology, Optical, General Health, Branches of biology, Medical technology, Medicine, Prosthetics, Neurotechnology, Medical devices, Emerging technologies, Neuroprosthetics, Visual prosthesis, Visual impairment, Neuromodulation, Implant

Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals.
  • The Companys U.S. headquarters are in Los Angeles, California, and European headquarters are in Lausanne, Switzerland.
  • We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Second Sight to Accelerate Development of Orion® Visual Cortical Prosthesis System

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Medical devices, Optical, Research, Science, General Health, Medical technology, Medicine, Branches of biology, Biomedical engineering, Prosthetics, Neuroprosthetics, Blindness, Emerging technologies, Visual prosthesis, Prosthesis, Glaucoma, Neuromodulation

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System (Orion).

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System (Orion).
  • Second Sight will continue providing support to existing Argus users worldwide while repositioning our resources to accelerate the market introduction of Orion.
  • Leveraging Second Sights 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight to Discuss First Quarter 2019 Financial Results on May 15, 2019 Conference Call

Retrieved on: 
Wednesday, May 8, 2019
Health, Medical devices, Medical technology, Prosthetics, Biotechnology, Biological engineering, Emerging technologies, Medical devices, Biomedical engineering, Neuroprosthetics, Visual prosthesis, Implant

A replay of the conference call will be available for two weeks after the call's completion by dialing (800)633-8284 (U.S.) or (402)977-9140 (International).

Key Points: 
  • A replay of the conference call will be available for two weeks after the call's completion by dialing (800)633-8284 (U.S.) or (402)977-9140 (International).
  • The archived webcast will be available for 30 days via the aforementioned URL.
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030 - Emphasis on the Novel Products and Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 30, 2019
Health, Optical, Corrective lenses, Medical technology, Optometry, Contact lens, Articles, Biotechnology, Prosthesis, Visual prosthesis

The Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030 report features an extensive study of the current market landscape of therapeutic contact lenses, drug-eluting contact lenses, diagnostic / monitoring contact lenses and visual prostheses.

Key Points: 
  • The Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030 report features an extensive study of the current market landscape of therapeutic contact lenses, drug-eluting contact lenses, diagnostic / monitoring contact lenses and visual prostheses.
  • The study lays emphasis on the novel products and technologies that are being developed for the treatment of ocular disorders, which generally cause severe visual impairment or blindness.
  • One of the key objectives of the report was to determine the existing market size and develop estimates of future growth opportunities for next-generation contact lenses and visual prostheses.
  • A detailed review of the landscape of novel ophthalmic products, highlighting the different categories of contact lenses and visual prostheses (bionic eye technologies) developed/being developed by various players across the world.

Second Sight Medical Products, Inc. Presents Positive Interim Results at the Fifth Annual BRAIN Initiative® Investigators Meeting

Retrieved on: 
Thursday, April 11, 2019
Surgery, Health, Medical devices, Optical, Articles, Life sciences, Biotechnology, Emerging technologies, Prosthetics, BRAIN Initiative, Neuroimaging, Neuroinformatics, Intelligence Advanced Research Projects Activity, DARPA, Visual prosthesis, Implant

The BRAIN InitiativeInvestigators Meeting convenes BRAIN Initiative awardees, staff, and leadership from the contributing federal agencies (NIH, NSF, DARPA, IARPA, and FDA), plus representatives and investigators from participating non-federal organizations.

Key Points: 
  • The BRAIN InitiativeInvestigators Meeting convenes BRAIN Initiative awardees, staff, and leadership from the contributing federal agencies (NIH, NSF, DARPA, IARPA, and FDA), plus representatives and investigators from participating non-federal organizations.
  • We are encouraged by the progress Orion subjects are making on visual function endpoints like square localization and direction of motion.
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.
  • We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.